Community Oncology Alliance

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

Community Oncology Alliance

2023 Community Oncology Conference
2022 Community Oncology Advocacy Summit
2021 Community Oncology Conference
2022 Community Oncology Conference
Events

Playback speed

10 seconds

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time -0:00

0.5x
0.75x
1x, selected
1.25x
1.5x
1.75x
2x

Chapters

descriptions off, selected

captions settings, opens captions settings dialog
captions off, selected

This is a modal window.

Beginning of dialog window. Escape will cancel and close the window.

TextColorTransparency

BackgroundColorTransparency

WindowColorTransparency

Font Size

Text Edge Style

Font Family

End of dialog window.

This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.

2021 Update on EGFR Exon20ins in mNSCLC: Bispecific Antibody vs. TKI Therapy Outcomes in Previously Treated Disease

By 2021 Community Oncology Conference FEATURING Alex Spira

0 views

May 24, 2021

This video was completed prior to amivantamab receiving FDA approval on 05/21/2021 and mobocertinib receiving ...
read more ↘ FDA approval on 9/15/2021.
↖ read less

Comments 0

A Heterogenous Disease with Varied Clinical Outcomes: HR+/HER2- MBC

Feat. J. O’Shaughnessy

Effects of PV Treatment on White Blood Cell Count and Thrombotic Risk

Feat. C. Harrison

2021 Community Oncology Conference